Survival of grafts of genetically modified cardiac myocytes transfected with FITC-labeled oligodeoxynucleotides and the β-galactosidase gene in the noninfarcted area, but not the myocardial infarcted area

Motokuni Aoki(Osaka City University), Toshio Ogihara(Osaka University), Shusaku Hayashi(Kyoto Pharmaceutical University), Naruya Tomita(M4 Engineering (United States)), Iwao Kida(The University of Osaka), Y Kaneda(The University of Osaka), Hidetsugu Matsushita, A Moriguchi(The University of Osaka), Ryuichi Morishita(The University of Osaka), Jitsuo Higaki(Saiseikai Matsuyama Hospital), Yoshiki Sawa(Osaka Police Hospital)
Gene Therapy
February 1, 1997
10.1038/sj.gt.3300361
Cited by 35

Related Papers

Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
|Hypertension Research|2014|1.4k
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
|The Lancet|2021|997
In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction
|Nature Medicine|1997|589
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
|Nature Medicine|1999|588
Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes
|Proceedings of the National Academy of Sciences|2010|501